Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) insider Linda Llewelyn sold 2,005 shares of the firm's stock in a transaction on Monday, April 15th. The stock was sold at an average price of $6.11, for a total transaction of $12,250.55. Following the transaction, the insider now directly owns 126,226 shares of the company's stock, valued at approximately $771,240.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Health Catalyst Price Performance
Shares of HCAT stock opened at $5.63 on Thursday. Health Catalyst, Inc. has a 1-year low of $5.51 and a 1-year high of $14.37. The company has a quick ratio of 4.42, a current ratio of 4.42 and a debt-to-equity ratio of 0.62. The stock has a 50 day simple moving average of $7.96 and a 200-day simple moving average of $8.46.
Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.06. The company had revenue of $75.08 million during the quarter, compared to analysts' expectations of $73.67 million. Health Catalyst had a negative net margin of 39.92% and a negative return on equity of 12.19%. As a group, equities research analysts anticipate that Health Catalyst, Inc. will post -0.47 earnings per share for the current year.
Wall Street Analyst Weigh In
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing | Ad
“Titan of Tech” Bets Big on Tiny AI Company
He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal…
But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him
Several brokerages have weighed in on HCAT. Piper Sandler reaffirmed an "overweight" rating and set a $15.00 price target (down from $17.00) on shares of Health Catalyst in a research report on Friday, February 23rd. Guggenheim upgraded Health Catalyst from a "neutral" rating to a "buy" rating and set a $14.00 price target for the company in a research report on Friday, January 26th. KeyCorp reissued a "sector weight" rating on shares of Health Catalyst in a report on Wednesday, April 10th. Barclays initiated coverage on shares of Health Catalyst in a research note on Wednesday, January 3rd. They set an "overweight" rating and a $14.00 price objective on the stock. Finally, Evercore ISI decreased their target price on shares of Health Catalyst from $11.00 to $10.00 and set an "outperform" rating for the company in a research note on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Health Catalyst presently has an average rating of "Moderate Buy" and a consensus price target of $12.10.
Get Our Latest Analysis on HCAT
Hedge Funds Weigh In On Health Catalyst
Several hedge funds and other institutional investors have recently made changes to their positions in HCAT. Nepsis Inc. raised its stake in Health Catalyst by 6.0% in the 1st quarter. Nepsis Inc. now owns 1,157,394 shares of the company's stock valued at $8,715,000 after purchasing an additional 65,462 shares during the last quarter. Los Angeles Capital Management LLC grew its holdings in shares of Health Catalyst by 386.6% during the first quarter. Los Angeles Capital Management LLC now owns 56,785 shares of the company's stock worth $428,000 after buying an additional 45,115 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Health Catalyst by 38.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,220,627 shares of the company's stock worth $11,303,000 after buying an additional 335,823 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Health Catalyst by 11.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,915 shares of the company's stock valued at $435,000 after buying an additional 4,941 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of Health Catalyst in the fourth quarter worth about $369,000. Hedge funds and other institutional investors own 85.00% of the company's stock.
About Health Catalyst
(
Get Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
